Mumbai: Mankind Pharma Ltd, India's fourth-largest pharmaceutical company by market share, is set to raise more than ₹9,000 crore through a mix of non-convertible debentures (NCDs) and short-term commercial paper as it ties up financing for its ₹13,630 crore acquisition of Bharat Serums and Vaccines Ltd (BSV) announced in late July.

孟买：按市场份额计算，印度第四大制药公司人类制药有限公司（Humany Pharma Ltd）将通过不可转换债券（NCDs）和短期商业票据的组合筹集9亿多雷亚尔，为其7月底宣布的以136.3亿雷亚尔收购巴拉特血清和疫苗有限公司（BSV）进行融资。

The average blended cost of the debt is likely to be around 8.50% with the firm seeking to borrow money over one- to-five years, said three people familiar with the plans. 'Bankers have already approached large mutual funds to place the debt, which will range from one year and may go up to five years looking at the demand,' said one of the persons cited above.

三位知情人士表示，由于该公司寻求在一到五年内借款，债务的平均混合成本可能在8.50%左右上述一位知情人士说，银行家们已经与大型共同基金接洽，以发行这些债务，从一年到五年不等。

'Most of the money will be raised from mutual funds while some insurance companies could also look to invest, especially at the longer end of the tenure,' the person said.The debt to be raised for the deal has been jointly underwritten by Deutsche Bank and Barclays Plc and is likely to be priced in the next few days, these people said.

这位知情人士说，大部分资金将从共同基金筹集，而一些保险公司也可能寻求投资，尤其是在任期较长的时候。这些知情人士表示，为该交易筹集的债务已由德意志银行（Deutsche Bank）和巴克莱银行（Barclays Plc）联合承销，可能在未来几天内定价。

A Barclays spokesperson declined to comment. Deutsche Bank didn't respond to queries.A Mankind Pharma spokesperson confirmed that the fund raising through bonds will be finalised within a few weeks. Apart from this, 'the company plans to raise Rs 2,000-3,000 crore through an equity issue this fiscal,' the spokesperson said.In May, Mankind's board approved an equity fundraising of Rs 7,500 crore, and also increased the borrowing limit to Rs 12,500 crore.

巴克莱发言人拒绝置评。德意志银行没有回应询问。人类制药公司发言人证实，通过债券筹集资金将在几周内完成。发言人说，除此之外，该公司计划在本财政年度通过股票发行筹集2000-3000亿卢比。5月，人类理事会批准了75亿卢比的股权融资，并将借款限额提高到12.5亿卢比。

Mankind is acquiring BSV from private equity firm Advent International. This will be the largest acquisition by the company that got listed a year ago and will make Mankind market leader in the fast-growing gynaecology-fertility or women's health segment with around 20% market share, edging past Emcure.

。这将是该公司一年前上市的最大一笔收购，将使人类市场在快速增长的妇科生育或女性健康领域处于领先地位，市场份额约为20%，超过Emcure。